Kenneth Ouriel

Ouriel was born in Rochester, New York, entered college at age 16, majored in biology and psychology at the University of Rochester and belonged to the fraternity Alpha Delta Phi. He was elected to Phi Beta Kappa in 1976 and graduated summa cum laude in 1977. He studied medicine at the University of Chicago and graduated in 1981 with Honors. He began a residency in general surgery at the University of Rochester Medical Center and completed a vascular surgical fellowship in 1987. He got a National Institutes of Health grant to study thrombosis and published results from a large, multicenter randomized trial of clot busting therapy in The New England Journal of Medicine in 1998. ==Career==

In 1998, he was recruited to the Cleveland Clinic as the chief of Vascular Surgery. He was promoted to Chief of Surgery in 2003 where he supervised 340 surgeons in the largest surgical department in the world. He authored three textbooks in vascular surgery "Ouriel said that the team inserted a Y-shaped tube through an incision in Dole's leg and placed it inside the weakened portion of the aorta. The aneurysm will eventually contract around the stent, which will remain in place for the rest of Dole's life," wrote a reporter. management of the health care facilities. In that connection, Ouriel matriculated in an Executive MBA program in global business jointly run by Columbia Business School and the London Business School. Ouriel was the CEO of the Sheikh Khalifa Medical City. Ouriel, as part of the UAE health authority, met with visiting dignitaries, including First Lady Laura Bush. Ouriel completed his master's degree in business administration from Columbia and London Business Schools. Ouriel facilitated the development of the first permanent renal transplantation program in the United Arab Emirates, where the Sheikh Khalifa team performed their first kidney transplant in early 2008. In 2010, Ouriel founded Syntactx, a contract medical research company that provides support for diagnostic labs, medical device and pharmaceutical companies in designing and carrying out clinical research trials, and thereafter led the company. It was announced in January 2021 that Syntactx was acquired by North American Science Associates (NAMSA). ==Publications==

• 1995, textbook, Lower Extremity Vascular Disease • 2001, paper, Peripheral arterial disease • 2013, paper, Reporting standards for adverse events after medical device use in the peripheral vascular system ==References==